keyword
MENU ▼
Read by QxMD icon Read
search

stereotactic ablative radiotherapy

keyword
https://www.readbyqxmd.com/read/28545199/cyberknife-radioablation-of-prostate-cancer-%C3%A2-preliminary-results-for-400-patients
#1
Leszek Miszczyk, Agnieszka Namysł Kaletka, Aleksandra Napieralska, Grzegorz Woźniak, Małgorzata Stąpór Fudzińska, Grzegorz Głowacki, Andrzej Tukiendorf
Objectives: To evaluate the tolerance and effectiveness of stereotactic ablative radiotherapy (SABR) applied in the treatment of low and intermediate risk (LR & IR) prostate cancer patients (PCP) and provide an evaluation of the level of risk group impact on treatment results. In addition, androgen deprivation therapy (ADT) usage and prostatic specific antigen (PSA) decline after SABR were assessed. Material and Methods: A total of 400 PCP (213 LR and 187 IR, including T2c) were irradiated with a CyberKnife using fd 7...
April 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28545098/survival-and-prognostic-factors-for-patients-with-advanced-hepatocellular-carcinoma-after-stereotactic-ablative-radiotherapy
#2
Cheng-Hsiang Lo, Jen-Fu Yang, Ming-Yueh Liu, Yee-Min Jen, Chun-Shu Lin, Hsing-Lung Chao, Wen-Yen Huang
OBJECTIVE: To evaluate the survival outcomes and prognostic factors of patients with advanced hepatocellular carcinoma (HCC) who underwent stereotactic ablative radiotherapy (SABR). METHODS: This retrospective study evaluated patients with advanced HCC who underwent SABR between December 2007 and July 2015. All patients had Barcelona Clinic Liver Cancer stage C disease and Child-Turcotte-Pugh (CTP) class A-B function. In-field control (IFC), overall survival (OS), prognostic factors, and toxicity were evaluated...
2017: PloS One
https://www.readbyqxmd.com/read/28535921/out-of-field-in-vivo-dosimetry-using-tld-in-sabr-for-primary-kidney-cancer-involving-mixed-photon-fields
#3
P Lonski, S Keehan, S Siva, D Pham, R D Franich, M L Taylor, T Kron
PURPOSE: To assess out-of-field dose using three different variants of LiF thermoluminescence dosimeters (TLD) for ten patients who underwent stereotactic ablative body radiotherapy (SABR) for primary renal cell carcinoma (RCC) and compare with treatment planning system (TPS) dose calculations. METHODS AND MATERIALS: Thermoluminescent dosimeter (TLD) measurements were conducted at 20, 30, 40 and 50cm from isocentre on ten patients undergoing SABR for primary RCC...
May 2017: Physica Medica: PM
https://www.readbyqxmd.com/read/28532400/oligometastases-from-prostate-cancer-local-treatment-with-stereotactic-body-radiotherapy-sbrt
#4
Gregor Habl, Christoph Straube, Kilian Schiller, Marciana Nona Duma, Markus Oechsner, Kerstin A Kessel, Matthias Eiber, Markus Schwaiger, Hubert Kübler, Jürgen E Gschwend, Stephanie E Combs
BACKGROUND: The impact of local tumor ablative therapy in oligometastasized prostate cancer (PC) is still under debate. To gain data for this approach, we evaluated oligometastasized PC patients receiving stereotactic body radiotherapy (SBRT) to bone metastases. METHODS: In this retrospective study, 15 oligometastasized PC patients with a total of 20 bone metastases were evaluated regarding biochemical progression-free survival (PSA-PFS), time to initiation of ADT, and local control rate (LCR)...
May 22, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28530067/-stereotactic-ablative-body-radiation-sabr-a-new-therapeutic-option-for-treatment-of-stage-i-lung-cancer
#5
REVIEW
Sarit Appel, Zvi Symon
Stereotactic ablative radiotherapy (SABR) also known as stereotactic body radiation therapy (SBRT) offers a new therapeutic option for stage 1 lung cancer that cannot undergo surgery due to co-morbidities or patient refusal. This treatment evolved in the last decade thanks to technologic advancement of radiation therapy planning and delivery that allow real time imaging of the tumor and real time position correction before every treatment. Ultra high doses of radiation cause ablation of the target with very low collateral scatter dose to surrounding tissue...
November 2016: Harefuah
https://www.readbyqxmd.com/read/28526616/stereotactic-ablative-radiotherapy-in-treatment-of-early-stage-non-small-cell-lung-cancer-unsolved-questions-and-frontiers-ahead
#6
Jingze Zhang, Li Kong, Qinghua Jiao, Minghuan Li, Jingming Yu
Stereotactic ablative radiotherapy (SABR) has been recognized as a standard alternative treatment to surgery for inoperable early stage non-small cell lung cancer (NSCLC). Guaranteed local control rates over 90% makes oncologists wonder whether SABR is qualified enough to challenge surgery in operable patients. The role of SABR for centrally located lesions would be another question because of the increased risk of severe toxic effect. Plenty of studies suggest that optimization of dose regimen and appropriate case selection would be helpful...
May 16, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28507888/spine-stereotactic-body-radiotherapy-indications-outcomes-and-points-of-caution
#7
Chia-Lin Tseng, Wietse Eppinga, Raphaele Charest-Morin, Hany Soliman, Sten Myrehaug, Pejman Jabehdar Maralani, Mikki Campbell, Young K Lee, Charles Fisher, Michael G Fehlings, Eric L Chang, Simon S Lo, Arjun Sahgal
STUDY DESIGN: A broad narrative review. OBJECTIVES: The objective of this article is to provide a technical review of spine stereotactic body radiotherapy (SBRT) planning and delivery, indications for treatment, outcomes, complications, and the challenges of response assessment. The surgical approach to spinal metastases is discussed with an overview of emerging minimally invasive techniques. METHODS: A comprehensive review of the literature was conducted on the techniques, outcomes, and developments in SBRT and surgery for spinal metastases...
April 2017: Global Spine Journal
https://www.readbyqxmd.com/read/28499791/the-role-of-radiotherapy-in-epidermal-growth-factor-receptor-mutation-positive-patients-with-oligoprogression-a-matched-cohort-analysis
#8
O S H Chan, V H F Lee, T S K Mok, F Mo, A T Y Chang, R M W Yeung
AIMS: Almost all patients with epidermal growth factor receptor (EGFR) mutations will develop resistance to first-line EGFR tyrosine kinase inhibitors (TKIs). The management of oligoprogression on EGFR TKI is controversial. Irradiating progressing tumours may potentially eradicate the resistant clone and allow continuation of EGFR TKI, but the clinical data remain sparse. We aimed to assess the effect of radiotherapy on survival outcomes in patients with oligoprogression in a matched-cohort study...
May 9, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28461786/prospective-evaluation-of-anxiety-depression-and-quality-of-life-in-medically-inoperable-early-stage-non-small-cell-lung-cancer-patients-treated-with-stereotactic-ablative-radiotherapy
#9
Jacek Rutkowski, Magdalena Szymanik, Maciej Blok, Joanna Kozaka, Renata Zaucha
AIM: The aim of this prospective study was to evaluate the level of anxiety, depression, and quality of life (QoL) in medically inoperable patients with early stage non-small cell lung cancer (NSCLC) treated with stereotactic ablative radiotherapy (SABR). BACKGROUND: Prolonged survival is equally important as maintaining high QoL and good psychological functioning during the treatment of lung cancer. Nowadays available SABR has markedly changed clinical care and outcomes in the group of medically inoperable patients...
May 2017: Reports of Practical Oncology and Radiotherapy
https://www.readbyqxmd.com/read/28460826/pulmonary-function-after-lung-tumor-stereotactic-ablative-radiotherapy-depends-on-regional-ventilation-within-irradiated-lung
#10
Michael S Binkley, Martin T King, Joseph B Shrager, Karl Bush, Aadel A Chaudhuri, Rita Popat, Michael F Gensheimer, Peter G Maxim, H Henry Guo, Maximilian Diehn, Viswam S Nair, Billy W Loo
PURPOSE: To determine if regional ventilation within irradiated lung volume predicts change in pulmonary function test (PFT) measurements after stereotactic ablative radiotherapy (SABR) of lung tumors. METHODS: We retrospectively identified 27 patients treated from 2007 to 2014 at our institution who received: (1) SABR without prior thoracic radiation; (2) pre-treatment 4-dimensional computed tomography (4-D CT) imaging; (3) pre- and post-SABR PFTs <15months from treatment...
May 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28454218/stereotactic-body-radiation-therapy-for-oligoprogression-of-metastatic-disease-from-gastrointestinal-cancers-a-novel-approach-to-extend-chemotherapy-efficacy
#11
Justin Wray, Rana Fawzi Hawamdeh, Nalini Hasija, Roi Dagan, Anamaria R Yeung, Judith L Lightsey, Paul Okunieff, Karen C Daily, Thomas J George, Robert A Zlotecki, Jose Trevino, Long H Dang
Chemotherapy and targeted therapies are effective palliative options for numerous unresectable or metastatic cancers. However, treatment resistance inevitably develops leading to mortality. In a subset of patients, systemic therapy appears to control the majority of tumors leaving 5 or less to progress, a phenomenon described as oligoprogression. Reasoning that the majority of lesions remain responsive to ongoing systemic chemotherapy, we hypothesized that local treatment of the progressing lesions would confer a benefit...
March 2017: Oncology Letters
https://www.readbyqxmd.com/read/28452968/immunomodulatory-effect-of-stereotactic-ablative-radiotherapy-in-lung-cancer
#12
Joanna Domagała-Kulawik
No abstract text is available yet for this article.
April 28, 2017: Polish Archives of Internal Medicine
https://www.readbyqxmd.com/read/28449482/retrospective-analysis-of-stereotactic-ablative-radiotherapy-sabr-for-metastatic-lung-lesions-mlls-in-comparison-with-a-contemporaneous-cohort-of-primary-lung-lesions-plls
#13
Feras Oskan, Yvonne Dzierma, Stefan Wagenpfeil, Christian Rübe, Jochen Fleckenstein
BACKGROUND: The net benefit from local ablative therapy for pulmonary oligometastases remains unknown. The outcomes of stereotactic ablative radiotherapy (SABR) for metastatic lung lesions (MLLs) were analyzed retrospectively and compared with those of SABR for primary lung lesions (PLLs). METHODS: Medical records of patients treated with lung SABR between 2011 and 2014 were retrospectively reviewed. Basic patient, lesion and treatment characteristics were compared using the Pearson chi-square test for categorical and Mann-Whitney U test for continuous variables...
March 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28447313/stereotactic-ablative-radiation-therapy-for-brain-metastases-with-volumetric-modulated-arc-therapy-and-flattening-filter-free-delivery-feasibility-and-early-clinical-results
#14
Alba Fiorentino, Niccolò Giaj-Levra, Umberto Tebano, Rosario Mazzola, Francesco Ricchetti, Sergio Fersino, Gioacchino Di Paola, Dario Aiello, Ruggero Ruggieri, Filippo Alongi
AIM: For selected patients with brain metastases (BMs), the role of stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (SFRT) is well recognized. The recent introduction of flattening filter free (FFF) delivery during linac-based SRS or SFRT allows shorter beam-on-time, improving patients' comfort and facility workflow. Nevertheless, limited experiences evaluated the impact of FFF linac-based SRS and SFRT in BMs treatment. Aim of the current study was to analyze SRS/SFRT linac-based FFF delivery for BMs in terms of dosimetric and early clinical results...
April 26, 2017: La Radiologia Medica
https://www.readbyqxmd.com/read/28433508/organs-at-risk-in-lung-sbrt
#15
REVIEW
F De Rose, D Franceschini, G Reggiori, A Stravato, P Navarria, A M Ascolese, S Tomatis, P Mancosu, M Scorsetti
Lung stereotactic body radiotherapy (SBRT) is an accurate and precise technique to treat lung tumors with high 'ablative' doses. Given the encouraging data in terms of local control and toxicity profile, SBRT has currently become a treatment option for both early stage lung cancer and lung oligometastatic disease in patients who are medically inoperable or refuse surgical resection. Dose-adapted fractionation schedules and ongoing prospective trials should provide further evidence of SBRT safety trying to reduce toxicities and complications...
April 19, 2017: Physica Medica: PM
https://www.readbyqxmd.com/read/28433413/stereotactic-ablative-radiotherapy-in-the-treatment-of-low-and-intermediate-risk-prostate-cancer-is-there-an-optimal-dose
#16
Joelle Helou, Laura D'Alimonte, Harvey Quon, Andrea Deabreu, Kristina Commisso, Patrick Cheung, William Chu, Alexandre Mamedov, Melanie Davidson, Ananth Ravi, Andrew Loblaw
PURPOSE: To investigate if stereotactic ablative radiotherapy (SABR) dose is associated with PSA at 3years (PSA3y) in the treatment of localized prostate cancer and to explore predictors of late genitourinary (GU) toxicity. MATERIALS AND METHODS: Three prospective trials of SABR were undertaken at our institution: 1) 35Gy/5 fractions/29days; 2) 40Gy/5 fractions/29days; 3) 40Gy/5 fractions/11 or 29days. PSA3y was analyzed as a continuous variable. Toxicity was defined as the worst new toxicity and assessed using the radiation therapy oncology group (RTOG) late morbidity scheme...
April 19, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28424839/reirradiation-of-recurrent-node-positive-non-small-cell-lung-cancer-after-previous-stereotactic-radiotherapy-for-stage%C3%A2-i-disease-a%C3%A2-multi-institutional-treatment-recommendation
#17
Carsten Nieder, Dirk De Ruysscher, Laurie E Gaspar, Matthias Guckenberger, Minesh P Mehta, Patrick Cheung, Arjun Sahgal
BACKGROUND: Practice guidelines have been developed for early-stage and locally advanced non-small cell lung cancer (NSCLC). However, many common clinical scenarios still require individualized decision making. This is true for locoregional relapse after initial stereotactic radiotherapy (stereotactic body radiation therapy or stereotactic ablative radiotherapy; SBRT or SABR), an increasingly utilized curative treatment option for stage I NSCLC. METHODS: A consortium of expert radiation oncologists was established with the aim of providing treatment recommendations...
April 19, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28420863/changes-in-systemic-immune-response-after-stereotactic-ablative-radiotherapy-preliminary-results-of-a-prospective-study-in-patients-with-early-lung-cancer
#18
Jacek Rutkowski, Tomasz Ślebioda, Zbigniew Kmieć, Renata Zaucha
INTRODUCTION    Non‑small cell lung cancer (NSCLC) is the most common lung tumor. Conventional conservative treatment in medically inoperable patients with early stage NSCLC has poor outcome. To improve treatment efficacy, stereotactic ablative radiotherapy (SABR) has been developed, which enables the delivery of high‑dose radiation to the tumor. OBJECTIVES    This prospective study was conducted to test the hypothesis that a sudden death of cancer cells after SABR may lead to changes in systemic immune response...
April 28, 2017: Polish Archives of Internal Medicine
https://www.readbyqxmd.com/read/28419246/quality-assurance-for-a-multicenter-phase-ii-study-of-stereotactic-ablative-radiotherapy-for-hepatocellular-carcinoma-%C3%A2-5-cm-a-planning-dummy-run
#19
Sun Hyun Bae, Mi-Sook Kim, Won Il Jang, Kum Bae Kim, Kwang Hwan Cho, Woo Chul Kim, Chang Yeol Lee, Eun Seog Kim, Chul Won Choi, A Ram Chang, Sunmi Jo, Jin-Young Kim
Objective: The Korean Radiation Oncology Group (12-02) investigated the outcome of stereotactic ablative radiotherapy for hepatocellular carcinoma ≤5 cm using 60 Gy in three fractions. To evaluate dosimetric differences and compliance in a multicenter trial, a planning dummy run procedure was performed. Methods: All six participating institutions were provided the contours of two dummy run cases. Plans were performed following the study protocol to cover the planning target volume with a minimum of 90% of the prescription dose and to satisfy the constraints for organs at risk...
April 13, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28409420/single-fraction-spine-stereotactic-ablative-body-radiotherapy-with-volumetric-modulated-arc-therapy
#20
Matthew M Gestaut, Nitika Thawani, Sangroh Kim, Veera R Gutti, Sameer Jhavar, Niloyjyoti Deb, Andrew Morrow, Russell A Ward, Jason H Huang, Mehul Patel
This study investigated a single institution's experience with volumetric modulated arc therapy (VMAT) directed stereotactic ablative body radiotherapy (SABR) for vertebral metastases. From 2010 to 2014, 95 lesions of spinal metastases in 73 patients were treated with SABR using VMAT. Clinical local control, pain level, and use of steroid medication were employed to evaluate treatment responses. The majority (79%) of patients were treated with a radiation dose of 20 Gy in a single fraction. However, when normal tissue constraints could not be achieved, the dose was reduced to 18 Gy (11%) or 16 Gy (8%) in 1 fraction...
April 13, 2017: Journal of Neuro-oncology
keyword
keyword
42615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"